Cost-effectiveness analysis of personalised versus standard dosimetry for selective internal radiation therapy with TheraSphere in patients with hepatocellular carcinoma
AimsTo perform a cost-effectiveness analysis (CEA) comparing personalised dosimetry with standard dosimetry in the context of selective internal radiation therapy (SIRT) with TheraSphere for the management of adult patients with locally advanced hepatocellular carcinoma (HCC) from the Italian Health...
| Main Authors: | , , , , , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2022-08-01
|
| Series: | Frontiers in Oncology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fonc.2022.920073/full |
| _version_ | 1817996152865292288 |
|---|---|
| author | Carla Rognoni Maria Rosa Barcellona Irene Bargellini Maria Grazia Bavetta Marilena Bellò Maurizia Brunetto Patrizia Carucci Roberto Cioni Laura Crocetti Fabio D’Amato Mario D’Amico Simona Deagostini Désirée Deandreis Paolo De Simone Andrea Doriguzzi Monica Finessi Paolo Fonio Serena Grimaldi Salvatore Ialuna Fabio Lagattuta Gianluca Masi Antonio Moreci Daniele Scalisi Roberto Virdone Rosanna Tarricone Rosanna Tarricone |
| author_facet | Carla Rognoni Maria Rosa Barcellona Irene Bargellini Maria Grazia Bavetta Marilena Bellò Maurizia Brunetto Patrizia Carucci Roberto Cioni Laura Crocetti Fabio D’Amato Mario D’Amico Simona Deagostini Désirée Deandreis Paolo De Simone Andrea Doriguzzi Monica Finessi Paolo Fonio Serena Grimaldi Salvatore Ialuna Fabio Lagattuta Gianluca Masi Antonio Moreci Daniele Scalisi Roberto Virdone Rosanna Tarricone Rosanna Tarricone |
| author_sort | Carla Rognoni |
| collection | DOAJ |
| description | AimsTo perform a cost-effectiveness analysis (CEA) comparing personalised dosimetry with standard dosimetry in the context of selective internal radiation therapy (SIRT) with TheraSphere for the management of adult patients with locally advanced hepatocellular carcinoma (HCC) from the Italian Healthcare Service perspective.Materials and methodsA partition survival model was developed to project costs and the quality-adjusted life years (QALYs) over a lifetime horizon. Clinical inputs were retrieved from a published randomised controlled trial. Health resource utilisation inputs were extracted from the questionnaires administered to clinicians in three oncology centres in Italy, respectively. Cost parameters were based on Italian official tariffs.ResultsOver a lifetime horizon, the model estimated the average QALYs of 1.292 and 0.578, respectively, for patients undergoing personalised and standard dosimetry approaches. The estimated mean costs per patient were €23,487 and €19,877, respectively. The incremental cost-utility ratio (ICUR) of personalised versus standard dosimetry approaches was €5,056/QALY.ConclusionsPersonalised dosimetry may be considered a cost-effective option compared to standard dosimetry for patients undergoing SIRT for HCC in Italy. These findings provide evidence for clinicians and payers on the value of personalised dosimetry as a treatment option for patients with HCC. |
| first_indexed | 2024-04-14T02:17:59Z |
| format | Article |
| id | doaj.art-b8b0c55e494f4f1685199dac22e29a7c |
| institution | Directory Open Access Journal |
| issn | 2234-943X |
| language | English |
| last_indexed | 2024-04-14T02:17:59Z |
| publishDate | 2022-08-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Oncology |
| spelling | doaj.art-b8b0c55e494f4f1685199dac22e29a7c2022-12-22T02:18:07ZengFrontiers Media S.A.Frontiers in Oncology2234-943X2022-08-011210.3389/fonc.2022.920073920073Cost-effectiveness analysis of personalised versus standard dosimetry for selective internal radiation therapy with TheraSphere in patients with hepatocellular carcinomaCarla Rognoni0Maria Rosa Barcellona1Irene Bargellini2Maria Grazia Bavetta3Marilena Bellò4Maurizia Brunetto5Patrizia Carucci6Roberto Cioni7Laura Crocetti8Fabio D’Amato9Mario D’Amico10Simona Deagostini11Désirée Deandreis12Paolo De Simone13Andrea Doriguzzi14Monica Finessi15Paolo Fonio16Serena Grimaldi17Salvatore Ialuna18Fabio Lagattuta19Gianluca Masi20Antonio Moreci21Daniele Scalisi22Roberto Virdone23Rosanna Tarricone24Rosanna Tarricone25Centre for Research on Health and Social Care Management (CERGAS), SDA Bocconi School of Management, Bocconi University, Milan, ItalyAzienda Ospedaliera Ospedali Riuniti Villa Sofia Cervello, Palermo, ItalyAzienda Ospedaliero Universitaria Pisana, Pisa, ItalyAzienda Ospedaliera Ospedali Riuniti Villa Sofia Cervello, Palermo, ItalyAzienda Ospedaliero Universitaria Città della Salute e della Scienza, Torino, ItalyAzienda Ospedaliero Universitaria Pisana, Pisa, ItalyAzienda Ospedaliero Universitaria Città della Salute e della Scienza, Torino, ItalyAzienda Ospedaliero Universitaria Pisana, Pisa, ItalyAzienda Ospedaliero Universitaria Pisana, Pisa, ItalyAzienda Ospedaliera Ospedali Riuniti Villa Sofia Cervello, Palermo, ItalyAzienda Ospedaliera Ospedali Riuniti Villa Sofia Cervello, Palermo, ItalyAzienda Ospedaliero Universitaria Città della Salute e della Scienza, Torino, ItalyAzienda Ospedaliero Universitaria Città della Salute e della Scienza, Torino, ItalyAzienda Ospedaliero Universitaria Pisana, Pisa, ItalyAzienda Ospedaliero Universitaria Città della Salute e della Scienza, Torino, ItalyAzienda Ospedaliero Universitaria Città della Salute e della Scienza, Torino, ItalyAzienda Ospedaliero Universitaria Città della Salute e della Scienza, Torino, ItalyAzienda Ospedaliero Universitaria Città della Salute e della Scienza, Torino, ItalyAzienda Ospedaliera Ospedali Riuniti Villa Sofia Cervello, Palermo, ItalyAzienda Ospedaliera Ospedali Riuniti Villa Sofia Cervello, Palermo, ItalyAzienda Ospedaliero Universitaria Pisana, Pisa, ItalyAzienda Ospedaliera Ospedali Riuniti Villa Sofia Cervello, Palermo, ItalyAzienda Ospedaliera Ospedali Riuniti Villa Sofia Cervello, Palermo, ItalyAzienda Ospedaliera Ospedali Riuniti Villa Sofia Cervello, Palermo, ItalyCentre for Research on Health and Social Care Management (CERGAS), SDA Bocconi School of Management, Bocconi University, Milan, ItalyDepartment of Policy Analysis and Public Management, Bocconi University, Milan, ItalyAimsTo perform a cost-effectiveness analysis (CEA) comparing personalised dosimetry with standard dosimetry in the context of selective internal radiation therapy (SIRT) with TheraSphere for the management of adult patients with locally advanced hepatocellular carcinoma (HCC) from the Italian Healthcare Service perspective.Materials and methodsA partition survival model was developed to project costs and the quality-adjusted life years (QALYs) over a lifetime horizon. Clinical inputs were retrieved from a published randomised controlled trial. Health resource utilisation inputs were extracted from the questionnaires administered to clinicians in three oncology centres in Italy, respectively. Cost parameters were based on Italian official tariffs.ResultsOver a lifetime horizon, the model estimated the average QALYs of 1.292 and 0.578, respectively, for patients undergoing personalised and standard dosimetry approaches. The estimated mean costs per patient were €23,487 and €19,877, respectively. The incremental cost-utility ratio (ICUR) of personalised versus standard dosimetry approaches was €5,056/QALY.ConclusionsPersonalised dosimetry may be considered a cost-effective option compared to standard dosimetry for patients undergoing SIRT for HCC in Italy. These findings provide evidence for clinicians and payers on the value of personalised dosimetry as a treatment option for patients with HCC.https://www.frontiersin.org/articles/10.3389/fonc.2022.920073/fulltrans-arterial radioembolisationcost-effectivenesscost-utilitypersonalised dosimetrytailored treatment |
| spellingShingle | Carla Rognoni Maria Rosa Barcellona Irene Bargellini Maria Grazia Bavetta Marilena Bellò Maurizia Brunetto Patrizia Carucci Roberto Cioni Laura Crocetti Fabio D’Amato Mario D’Amico Simona Deagostini Désirée Deandreis Paolo De Simone Andrea Doriguzzi Monica Finessi Paolo Fonio Serena Grimaldi Salvatore Ialuna Fabio Lagattuta Gianluca Masi Antonio Moreci Daniele Scalisi Roberto Virdone Rosanna Tarricone Rosanna Tarricone Cost-effectiveness analysis of personalised versus standard dosimetry for selective internal radiation therapy with TheraSphere in patients with hepatocellular carcinoma Frontiers in Oncology trans-arterial radioembolisation cost-effectiveness cost-utility personalised dosimetry tailored treatment |
| title | Cost-effectiveness analysis of personalised versus standard dosimetry for selective internal radiation therapy with TheraSphere in patients with hepatocellular carcinoma |
| title_full | Cost-effectiveness analysis of personalised versus standard dosimetry for selective internal radiation therapy with TheraSphere in patients with hepatocellular carcinoma |
| title_fullStr | Cost-effectiveness analysis of personalised versus standard dosimetry for selective internal radiation therapy with TheraSphere in patients with hepatocellular carcinoma |
| title_full_unstemmed | Cost-effectiveness analysis of personalised versus standard dosimetry for selective internal radiation therapy with TheraSphere in patients with hepatocellular carcinoma |
| title_short | Cost-effectiveness analysis of personalised versus standard dosimetry for selective internal radiation therapy with TheraSphere in patients with hepatocellular carcinoma |
| title_sort | cost effectiveness analysis of personalised versus standard dosimetry for selective internal radiation therapy with therasphere in patients with hepatocellular carcinoma |
| topic | trans-arterial radioembolisation cost-effectiveness cost-utility personalised dosimetry tailored treatment |
| url | https://www.frontiersin.org/articles/10.3389/fonc.2022.920073/full |
| work_keys_str_mv | AT carlarognoni costeffectivenessanalysisofpersonalisedversusstandarddosimetryforselectiveinternalradiationtherapywiththerasphereinpatientswithhepatocellularcarcinoma AT mariarosabarcellona costeffectivenessanalysisofpersonalisedversusstandarddosimetryforselectiveinternalradiationtherapywiththerasphereinpatientswithhepatocellularcarcinoma AT irenebargellini costeffectivenessanalysisofpersonalisedversusstandarddosimetryforselectiveinternalradiationtherapywiththerasphereinpatientswithhepatocellularcarcinoma AT mariagraziabavetta costeffectivenessanalysisofpersonalisedversusstandarddosimetryforselectiveinternalradiationtherapywiththerasphereinpatientswithhepatocellularcarcinoma AT marilenabello costeffectivenessanalysisofpersonalisedversusstandarddosimetryforselectiveinternalradiationtherapywiththerasphereinpatientswithhepatocellularcarcinoma AT mauriziabrunetto costeffectivenessanalysisofpersonalisedversusstandarddosimetryforselectiveinternalradiationtherapywiththerasphereinpatientswithhepatocellularcarcinoma AT patriziacarucci costeffectivenessanalysisofpersonalisedversusstandarddosimetryforselectiveinternalradiationtherapywiththerasphereinpatientswithhepatocellularcarcinoma AT robertocioni costeffectivenessanalysisofpersonalisedversusstandarddosimetryforselectiveinternalradiationtherapywiththerasphereinpatientswithhepatocellularcarcinoma AT lauracrocetti costeffectivenessanalysisofpersonalisedversusstandarddosimetryforselectiveinternalradiationtherapywiththerasphereinpatientswithhepatocellularcarcinoma AT fabiodamato costeffectivenessanalysisofpersonalisedversusstandarddosimetryforselectiveinternalradiationtherapywiththerasphereinpatientswithhepatocellularcarcinoma AT mariodamico costeffectivenessanalysisofpersonalisedversusstandarddosimetryforselectiveinternalradiationtherapywiththerasphereinpatientswithhepatocellularcarcinoma AT simonadeagostini costeffectivenessanalysisofpersonalisedversusstandarddosimetryforselectiveinternalradiationtherapywiththerasphereinpatientswithhepatocellularcarcinoma AT desireedeandreis costeffectivenessanalysisofpersonalisedversusstandarddosimetryforselectiveinternalradiationtherapywiththerasphereinpatientswithhepatocellularcarcinoma AT paolodesimone costeffectivenessanalysisofpersonalisedversusstandarddosimetryforselectiveinternalradiationtherapywiththerasphereinpatientswithhepatocellularcarcinoma AT andreadoriguzzi costeffectivenessanalysisofpersonalisedversusstandarddosimetryforselectiveinternalradiationtherapywiththerasphereinpatientswithhepatocellularcarcinoma AT monicafinessi costeffectivenessanalysisofpersonalisedversusstandarddosimetryforselectiveinternalradiationtherapywiththerasphereinpatientswithhepatocellularcarcinoma AT paolofonio costeffectivenessanalysisofpersonalisedversusstandarddosimetryforselectiveinternalradiationtherapywiththerasphereinpatientswithhepatocellularcarcinoma AT serenagrimaldi costeffectivenessanalysisofpersonalisedversusstandarddosimetryforselectiveinternalradiationtherapywiththerasphereinpatientswithhepatocellularcarcinoma AT salvatoreialuna costeffectivenessanalysisofpersonalisedversusstandarddosimetryforselectiveinternalradiationtherapywiththerasphereinpatientswithhepatocellularcarcinoma AT fabiolagattuta costeffectivenessanalysisofpersonalisedversusstandarddosimetryforselectiveinternalradiationtherapywiththerasphereinpatientswithhepatocellularcarcinoma AT gianlucamasi costeffectivenessanalysisofpersonalisedversusstandarddosimetryforselectiveinternalradiationtherapywiththerasphereinpatientswithhepatocellularcarcinoma AT antoniomoreci costeffectivenessanalysisofpersonalisedversusstandarddosimetryforselectiveinternalradiationtherapywiththerasphereinpatientswithhepatocellularcarcinoma AT danielescalisi costeffectivenessanalysisofpersonalisedversusstandarddosimetryforselectiveinternalradiationtherapywiththerasphereinpatientswithhepatocellularcarcinoma AT robertovirdone costeffectivenessanalysisofpersonalisedversusstandarddosimetryforselectiveinternalradiationtherapywiththerasphereinpatientswithhepatocellularcarcinoma AT rosannatarricone costeffectivenessanalysisofpersonalisedversusstandarddosimetryforselectiveinternalradiationtherapywiththerasphereinpatientswithhepatocellularcarcinoma AT rosannatarricone costeffectivenessanalysisofpersonalisedversusstandarddosimetryforselectiveinternalradiationtherapywiththerasphereinpatientswithhepatocellularcarcinoma |